Yulan Wang1, Tianxing Deng2, Li Zeng1, Weiqing Chen1. 1. Department of Gastroenterology, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. 2. Department of Urology, Second Affiliated Hospital, Third Military Medical University, Chongqing, China.
Abstract
AIM: To investigate the efficacy and safety of radiofrequency ablation (RFA) and transcatheter arterial chemoembolization (TACE) for treatment of patients with hepatocellular carcinoma (HCC). METHODS: All eligible studies were collected from PubMed, the Cochrane Libraries and Embase. The evaluation indices included overall survival (OS) rate, recurrence-free survival rate, local tumor progression rate and major complications. All statistical analysis was performed by RevMan version 5.2 software. RESULTS: There were 21 studies with 3073 patients included in this meta-analysis. The RFA monotherapy was associated with higher 3- and 5-year OS rates (OR3-year = 2.33, 95% confidence interval [CI] = 1.34-4.05; OR5-year = 2.05, 95% CI = 1.48-2.85) compared with TACE alone. The combination of RFA and TACE was associated with higher 1-, 3- and 5-year OS rates (OR1-year = 1.94, 95% CI = 1.28-2.96; OR3-year = 1.56, 95% CI = 1.19-2.04; OR5-year = 1.53, 95% CI = 1.13-2.07) compared with RFA alone. CONCLUSION: The combination of TACE with RFA could obviously improve the short- and long-term survival rates and significantly provide a better prognosis for patients with intermediate-size HCC. RFA was associated with a higher long-term OS rate than that of TACE-treated patients with HCC.
AIM: To investigate the efficacy and safety of radiofrequency ablation (RFA) and transcatheter arterial chemoembolization (TACE) for treatment of patients with hepatocellular carcinoma (HCC). METHODS: All eligible studies were collected from PubMed, the Cochrane Libraries and Embase. The evaluation indices included overall survival (OS) rate, recurrence-free survival rate, local tumor progression rate and major complications. All statistical analysis was performed by RevMan version 5.2 software. RESULTS: There were 21 studies with 3073 patients included in this meta-analysis. The RFA monotherapy was associated with higher 3- and 5-year OS rates (OR3-year = 2.33, 95% confidence interval [CI] = 1.34-4.05; OR5-year = 2.05, 95% CI = 1.48-2.85) compared with TACE alone. The combination of RFA and TACE was associated with higher 1-, 3- and 5-year OS rates (OR1-year = 1.94, 95% CI = 1.28-2.96; OR3-year = 1.56, 95% CI = 1.19-2.04; OR5-year = 1.53, 95% CI = 1.13-2.07) compared with RFA alone. CONCLUSION: The combination of TACE with RFA could obviously improve the short- and long-term survival rates and significantly provide a better prognosis for patients with intermediate-size HCC. RFA was associated with a higher long-term OS rate than that of TACE-treated patients with HCC.
Authors: Ashraf Omar Abdelaziz; Ahmed Hosni Abdelmaksoud; Mohamed Mahmoud Nabeel; Hend Ibrahim Shousha; Ahmed Abdelmonem Cordie; Sherif Hamdy Mahmoud; Eman Medhat; Dalia Omran; Tamer Mahmoud Elbaz Journal: Asian Pac J Cancer Prev Date: 2017-01-01
Authors: Fabio Farinati; Alessandro Vitale; Gaya Spolverato; Timothy M Pawlik; Teh-la Huo; Yun-Hsuan Lee; Anna Chiara Frigo; Anna Giacomin; Edoardo G Giannini; Francesca Ciccarese; Fabio Piscaglia; Gian Lodovico Rapaccini; Mariella Di Marco; Eugenio Caturelli; Marco Zoli; Franco Borzio; Giuseppe Cabibbo; Martina Felder; Rodolfo Sacco; Filomena Morisco; Elisabetta Biasini; Francesco Giuseppe Foschi; Antonio Gasbarrini; Gianluca Svegliati Baroni; Roberto Virdone; Alberto Masotto; Franco Trevisani; Umberto Cillo Journal: PLoS Med Date: 2016-04-26 Impact factor: 11.069
Authors: Young Mi Hong; Ki Tae Yoon; Mong Cho; Dae Hwan Kang; Hyung Wook Kim; Cheol Woong Choi; Su Bum Park; Jeong Heo; Hyun Young Woo; Won Lim Journal: J Korean Med Sci Date: 2016-02-17 Impact factor: 2.153